IVVD logo

Invivyd, Inc.

IVVD
Healthcare|Biotechnology|US
$0.56
-0.02 (-3.76%)
DCF Value
$10.71
Tangible Book / Share
$0.57
Cash / Share
$0.50

Clinical Trials (9)

TrialConditionsPhaseStatusEnrollmentDesignDrug
NCT07298434
Study of VYD2311 for the Prevention of COVID-19
COVID-19
P3
Active1,770RCT, Double-blindVYD2311-SD, VYD2311-MD, Placebo
NCT06523153
A Study of the Investigational Monoclonal Antibody, VYD2311, in Healthy Participants
COVID-19
P1
Active40RCT, Double-blindVYD2311
NCT06039449
A Study to Investigate the Prevention of COVID-19 WithVYD222 in Adults with Immune Compromise and in Participants Aged 12 Years or Older Who Are At Risk of Exposure to SARS-CoV-2
COVID-19, SARS-CoV-2
P3
Completed790RCT, Double-blindVYD222 (pemivibart), Normal saline
NCT07655180
Safety and Serum Virus Neutralizing Antibody Responses of VYD2311, a COVID-19 Vaccine, and Coadministered VYD2311 With a COVID-19 Vaccine
COVID-19
P3
Completed210RCT, Double-blindCOVID-19 mRNA vaccine, VYD2311, Placebo (Normal Saline)
NCT04859517
Evaluation of ADG20 for the Prevention of COVID-19
COVID-19
P2P3
Terminated2,582RCT, Double-blindADG20, Placebo
NCT04805671
Evaluation of ADG20 for the Treatment of Mild or Moderate COVID-19
COVID-19
P2P3
Terminated399RCT, Double-blindADG20, Normal saline
NCT07899346
Study of VYD2311 for the Treatment of Adults With Long-COVID or Post-Vaccination Syndrome
Long COVID, COVID-19 (SARS-CoV-2 Infection)
P2
Not Yet Recruiting130RCT, Double-blindVYD2311, Placebo
NCT05791318
A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of the Monoclonal Antibody VYD222 in Healthy Adult Participants
COVID-19
P1
Completed30RCT, Double-blindVYD222
NCT06004128
Provide Pre-approval Single-patient Expanded Access (Compassionate Use) of VYD222 for Patients With Symptomatic COVID-19 Refractory to Other Treatments
COVID-19
NO_LONGER_AVAILABLE——VYD222